Vaccine Protection Against Zika Virus from Brazil

DSpace/Manakin Repository

Vaccine Protection Against Zika Virus from Brazil

Citable link to this page

 

 
Title: Vaccine Protection Against Zika Virus from Brazil
Author: Larocca, Rafael A.; Abbink, Peter; Peron, Jean Pierre S.; de A. Zanotto, Paolo M.; Iampietro, M. Justin; Badamchi-Zadeh, Alexander; Boyd, Michael; Ng’ang’a, David; Kirilova, Marinela; Nityanandam, Ramya; Mercado, Noe B.; Li, Zhenfeng; Moseley, Edward T.; Bricault, Christine A.; Borducchi, Erica N.; Giglio, Patricia B.; Jetton, David; Neubauer, George; Nkolola, Joseph P.; Maxfield, Lori F.; De La Barrera, Rafael A.; Jarman, Richard G.; Eckels, Kenneth H.; Michael, Nelson L.; Thomas, Stephen J.; Barouch, Dan H.

Note: Order does not necessarily reflect citation order of authors.

Citation: Larocca, R. A., P. Abbink, J. P. S. Peron, P. M. de A. Zanotto, M. J. Iampietro, A. Badamchi-Zadeh, M. Boyd, et al. 2016. “Vaccine Protection Against Zika Virus from Brazil.” Nature 536 (7617): 474-478. doi:10.1038/nature18952. http://dx.doi.org/10.1038/nature18952.
Full Text & Related Files:
Abstract: Zika virus (ZIKV) is a flavivirus that is responsible for an unprecedented current epidemic in Brazil and the Americas1,2. ZIKV has been causally associated with fetal microcephaly, intrauterine growth restriction, and other birth defects in both humans3–8 and mice9–11. The rapid development of a safe and effective ZIKV vaccine is a global health priority1,2, but very little is currently known about ZIKV immunology and mechanisms of immune protection. Here we show that a single immunization of a plasmid DNA vaccine or a purified inactivated virus vaccine provides complete protection in susceptible mice against challenge with a ZIKV outbreak strain from northeast Brazil. This ZIKV strain has recently been shown to cross the placenta and to induce fetal microcephaly and other congenital malformations in mice11. We produced DNA vaccines expressing full-length ZIKV pre-membrane and envelope (prM-Env) as well as a series of deletion mutants. The full-length prM-Env DNA vaccine, but not the deletion mutants, afforded complete protection against ZIKV as measured by absence of detectable viremia following challenge, and protective efficacy correlated with Env-specific antibody titers. Adoptive transfer of purified IgG from vaccinated mice conferred passive protection, and CD4 and CD8 T lymphocyte depletion in vaccinated mice did not abrogate protective efficacy. These data demonstrate that protection against ZIKV challenge can be achieved by single-shot subunit and inactivated virus vaccines in mice and that Env-specific antibody titers represent key immunologic correlates of protection. Our findings suggest that the development of a ZIKV vaccine for humans will likely be readily achievable.
Published Version: doi:10.1038/nature18952
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003703/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:31731783
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters